Lixue Xuan
Overview
Explore the profile of Lixue Xuan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lei C, Li Y, Yang H, Zhang K, Lu W, Wang N, et al.
Front Mol Biosci
. 2024 May;
11:1394585.
PMID: 38751445
Objective: Breast cancer is highly heterogeneous, presenting challenges in prognostic assessment. Developing a universally applicable prognostic model could simplify clinical decision-making. This study aims to develop and validate a novel...
2.
Lei C, Kong X, Li Y, Yang H, Zhang K, Wang Z, et al.
J Cancer
. 2024 Apr;
15(9):2770-2787.
PMID: 38577606
As the positive results of multiple clinical trials were released, the Programmed cell death 1 (PD-1) and Programmed cell death ligand 1 (PD-L1) inhibitors emerge as the focus of integrative...
3.
Zhang K, Li Y, Kong X, Lei C, Yang H, Wang N, et al.
Front Oncol
. 2023 May;
13:1195885.
PMID: 37197416
AGR2 is a secreted protein widely existing in breast. In precancerous lesions, primary tumors and metastatic tumors, the expression of AGR2 is increased, which has aroused our interest. This review...
4.
Feng K, Zhao S, Shang Q, Qiao G, Liu J, Yang C, et al.
Cancer Cell Int
. 2022 Nov;
22(1):357.
PMID: 36376836
Background: Due to the rarity of PBL and the lack of large-scale studies, the prognostic value of IPI in PBL was controversial. Especially in the rituximab era, the ability of...
5.
Zhang K, Kong X, Li Y, Wang Z, Zhang L, Xuan L
Front Pharmacol
. 2022 Apr;
13:854967.
PMID: 35370736
Autoimmune diseases and malignant tumors are the two hotspots and difficulties that are currently being studied and concerned by the medical field. The use of PD-1/PD-L1 inhibitors improves the prognosis...
6.
Li Y, Kong X, Wang Z, Xuan L
J Cell Mol Med
. 2022 Feb;
26(5):1351-1362.
PMID: 35150062
Triple-negative breast cancer (TNBC), a heterogeneous tumour that lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), is often characterized by...
7.
Li Y, Kong X, Xuan L, Wang Z, Huang Y
J Cell Mol Med
. 2021 Oct;
25(22):10327-10348.
PMID: 34651424
Breast cancer, a hormone-dependent tumour, generally includes four molecular subtypes (luminal A, luminal B, HER2 enriched and triple-negative) based on oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2....
8.
Yang Z, Lan X, Huang Z, Yang Y, Tang Y, Jing H, et al.
Breast
. 2020 Aug;
53:143-151.
PMID: 32823167
Objective: To develop a nomogram for predicting the possibility of four or more positive nodes in breast cancer patients with 1-3 positive sentinel lymph nodes (SLN). Materials And Methods: Retrospective...
9.
Zhai J, Kong X, Yang X, Gao J, Xuan L, Wang X, et al.
Onco Targets Ther
. 2018 Jul;
11:3685-3690.
PMID: 29983576
Granulocytic sarcoma (GS) is an uncommon extramedullary manifestation of acute myeloid leukemia. GS is often likely to be clinically misdiagnosed as another type of primary breast cancer due to its...
10.
Zuo T, Zeng H, Li H, Liu S, Yang L, Xia C, et al.
Chin J Cancer
. 2017 Oct;
36(1):84.
PMID: 29070080
Background: Stage at diagnosis and molecular subtype are important clinical factors associated with breast cancer patient survival. However, subgroup survival data from a large study sample are limited in China....